FierceBiotechOriginal article
{"a":[{"_":"Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody","$":{"href":"/biotech/roche-inks-153-billion-biobucks-deal-simceres-b-cell-targeting-antibody","hreflang":"en"}}]}
Trispecific antibodyPositive
AI Analysis
Summary
Roche is acquiring global rights to Simcere Zaiming's preclinical trispecific antibody targeting B-cell-mediated diseases in a deal valued at $1.53 billion, with $75 million upfront.
Importance:7/10
Sentiment:
0.60
acquisitiononcologyantibodypreclinicalB-cellpartnership
Related Companies
Read the original article
Published by FierceBiotech on September 1, 2026 10:01 AM
